An interventional study of A and B in Diabetes Mellitus, Type 2 and Cardiovascular Disease, sponsored by TNO. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-05-23.
Sponsored by TNO · Not applicable, Interventional, and Prevention
Moderate alcohol consumption is associated with a decreased risk of diabetes type 2. This association could be mediated by an improvement of insulin sensitivity with moderate alcohol consumption. Patients with diabetes type 2 or impaired glucose tolerance often may have decreased fat oxidative capacity or oxidative phosphorylation in tissue such as muscle. This could lead to accumulation triglyceride storage in muscle, which could interfere with insulin signaling. Whether such mechanism can also play a role with moderate alcohol consumption is unknown and will be investigated in this study.
In addition, moderate alcohol consumption with a meal can lead to delayed hypoglycemia in type 1 diabetes patients. How moderate alcohol consumption affects postprandial glycemic response in healthy subjects is unknown. This is a secondary objective of this trial.
To investigate the effect of moderate alcohol consumption on
Design : Open, randomized, partially diet-controlled, placebo controlled cross-over design
Participants
Study substances
Duration: 2 treatment periods of 4 weeks (28 days)
Test parameters:
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's enrollment of 19 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →TNO is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Whiskey (32 gram of alcohol/day)
Dietary Supplement: A
Water (0 gram alcohol/day)
Dietary Supplement: B
Alcohol consumption (32 g/day) for 4 weeks
Water
enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle
Time frame: 4 weeks
Post-prandial glycemic response
Time frame: 4 weeks
insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)
Time frame: 4 weeks
No study locations are listed for this record.
This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TNO